Clinical Research Directory

Inclusion Criteria: * Participant with diagnosis of moderate or severe chronic plaque PSO documented in the medical chart. * Participant who needs systemic biologic therapy and qualifies for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-Il-23p19 selected therapy before including the patient in the study. * Participant aged greater than or equal to (\>=) 18 years at Inclusion. * Written informed consent. Exclusion Criteria: * Participant unable or unwilling to comply with the requirements of the study. * Participant who should not participate in the study for any reason at the discretion of the treating physician. * Participants participating in a simultaneous clinical trial. * Any contraindication against the use of Tildrakizumab according to the SmPC. * Exposure to \>= 3 biologics prior to inclusion. * Participant dependent on the investigator, e.g. as employee